Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
NATIONAL INSTITUTES OF HEALTH has floated a tender for NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional). The project location is USA and the tender is closing on 05 Jan 2021. The tender notice number is PAR-18-665, while the TOT Ref Number is 20695408. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : USA
Summary : NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
Deadline : 05 Jan 2021
Other Information
Notice Type : Tender
TOT Ref.No.: 20695408
Document Ref. No. : PAR-18-665
Competition : ICB
Financier : Self Financed
Purchaser Ownership : -
Tender Value : Refer Document
Purchaser's Detail
Purchaser : NATIONAL INSTITUTES OF HEALTH
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
USA
Email :FBOWebmaster@OD.NIH.GOV
Tender Details
Tender are invited for NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional)
CFDA Number : 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders
Cost Sharing or Matching Requirement : No
Closing Date for Applications: Jan 05, 2021
Posted Date : Feb 15, 2018
Description: This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support clinical trials for projects that were previously funded by NIH SBIR and STTR Phase II awards. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of SBIR Phase II projects to the commercialization stage by promoting partnerships between NIHs SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.
Documents
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google